Benjamin Ettle

Nuernberg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab.

Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab.

Journal: Human vaccines & immunotherapeutics

Published: February 12, 2024

Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis.

Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis.

Journal: Vaccines

Published: April 16, 2023

Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab.

Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab.

Journal: Vaccines

Published: November 23, 2022

Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany.

Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: October 11, 2021

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.

Journal: Journal of neurology

Published: August 16, 2021

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients.

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients.

Journal: Frontiers in neurology

Published: December 02, 2020

The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution study.

The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution study.

Journal: Multiple sclerosis and related disorders

Published: July 27, 2020

Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis.

Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis.

Journal: PharmacoEconomics

Published: May 15, 2020

Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis.

Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis.

Journal: PharmacoEconomics

Published: May 05, 2020

Patient- versus physician-reported relapses in multiple sclerosis: insights from a large observational study.

Patient- versus physician-reported relapses in multiple sclerosis: insights from a large observational study.

Journal: European journal of neurology

Published: March 20, 2020

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study.

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study.

Journal: Journal of medical Internet research

Published: January 22, 2020

Correction to: Differentiating societal costs of disability worsening in multiple sclerosis.

Correction to: Differentiating societal costs of disability worsening in multiple sclerosis.

Journal: Journal of neurology

Published: January 18, 2020

Showing 1-12 of 28

Last Updated: 09/26/2026